Plus Therapeutics Announces Selection of "Rhenium (186Re) Obisbemeda" as International Non-Proprietary Name for 186RNL
Stock Information for PLUS THERAPEUTICS Inc.
Please wait while we load your information from QuoteMedia.
More Recent News About PLUS THERAPEUTICS Inc.
Plus Therapeutics Announces Topline Results from Recurrent Glioblastoma External Control Analysis at ASCO 2023
Plus Therapeutics Expands Collaboration with Piramal Pharma Solutions to Meet Increase in Investigational Drug Demand for Ongoing and Planned Clinical Trials